세계의 중추신경계 치료제 시장 : 질환별, 약제 유형별, 투여경로별, 최종사용자별 예측(2025-2030년)

The Central Nervous System Therapeutics Market was valued at USD 133.83 billion in 2023, expected to reach USD 143.11 billion in 2024, and is projected to grow at a CAGR of 7.24%, to USD 218.45 billion by 2030.

The Central Nervous System (CNS) Therapeutics market encompasses a broad range of treatments targeting neurological disorders and diseases, including Alzheimer's, Parkinson's, multiple sclerosis, and depression. This market is driven by the increasing prevalence of neurological disorders due to aging populations, rising awareness, and expanding healthcare access. The necessity for CNS therapeutics is underscored by the significant social and economic burden posed by these diseases, making innovative treatment options and improved patient outcomes critical. Applications span across pharmaceuticals, gene and cell therapies, and innovative delivery systems, catering to both acute and chronic aspects of CNS disorders. Key end-users include hospitals, clinics, and research institutions. Market growth is influenced by advancements in drug delivery technologies, improved diagnostic techniques, and an influx of novel biologics. Opportunities abound in the exploration of personalized medicine, with a focus on genomics to create targeted therapies. Collaborative efforts in R&D, artificial intelligence utilization for drug discovery, and regulatory incentives like orphan drug designation are potential routes to capitalize on burgeoning opportunities. However, the market faces limitations such as significant R&D costs, stringent regulatory landscapes, and challenges in penetrating developing regions due to infrastructure hurdles. The scarcity of predictive model systems and difficulty in crossing the blood-brain barrier remain persistent challenges. To address these, innovation in biomarkers, improved clinical trial designs, and brain scaffold technologies could be transformative. The nature of the CNS therapeutics market is dynamic, with a high-risk, high-reward profile demanding continuous innovation and agility. Companies are advised to invest in collaborative research, foster strategic partnerships, and leverage technological advancements while navigating the regulatory and operational challenges. Focusing on comprehensive patient care solutions and leveraging digital health technologies could create a sustainable competitive edge in this evolving landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Central Nervous System Therapeutics Market

The Central Nervous System Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing elderly population and the prevalence of neurodegenerative disorders
  • Implementation of government initiatives & funding for research on neurological disorders
• Market Restraints
  • Rising cases of product recall associated with the CNS drugs
• Market Opportunities
  • Investment in gene-editing technologies and stem cell research for neurodegenerative diseases
  • Potential utilization of nanomaterials for innovative drug formulation
• Market Challenges
  • Complexities of CNS disorders coupled with difficulty in crossing the blood-brain barrier

Porter's Five Forces: A Strategic Tool for Navigating the Central Nervous System Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Central Nervous System Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Central Nervous System Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Central Nervous System Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Central Nervous System Therapeutics Market

A detailed market share analysis in the Central Nervous System Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Central Nervous System Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Central Nervous System Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Central Nervous System Therapeutics Market

A strategic analysis of the Central Nervous System Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Central Nervous System Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Acorda Therapeutics, Inc., Alkermes PLC, Amgen Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Cassava Sciences, Inc., Cipla Limited, CNS Pharmaceuticals, Inc., Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, H. Lundbeck A/S, Intra-Cellular Therapies, Inc., Ipsen S.A., Johnson & Johnson Services, Inc., Lupin Limited, MapLight Therapeutics, Inc., Merck KGaA, Minerva Neurosciences, Inc., Neuraxpharm, Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co Ltd, Pfizer Inc., Polpharma Biologics S.A., Rapport Therapeutics, Inc., Sage Therapeutics, Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, TauRx Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Central Nervous System Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disorders, market is studied across Epileptic Disorders, Neurodegenerative Diseases, Pain Management, and Psychiatric Disorders. The Epileptic Disorders is further studied across Epilepsy and Seizure Disorders. The Neurodegenerative Diseases is further studied across Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson's Disease. The Pain Management is further studied across Acute Pain, Chronic Pain, and Neuropathic Pain. The Psychiatric Disorders is further studied across Anxiety Disorders, Bipolar Disorder, Depression, and Schizophrenia.
• Based on Drug Type, market is studied across Biologics and Small Molecules. The Biologics is further studied across Gene Therapies, Monoclonal Antibodies, Peptides, and Stem Cell Therapies.
• Based on Route of Administration, market is studied across Injectable, Oral, and Transdermal. The Injectable is further studied across Intramuscular, Intravenous, and Subcutaneous.
• Based on End-Users, market is studied across Hospitals, Research Institutes, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing elderly population and the prevalence of neurodegenerative disorders
    • 5.1.1.2. Implementation of government initiatives & funding for research on neurological disorders
  • 5.1.2. Restraints
    • 5.1.2.1. Rising cases of product recall associated with the CNS drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Investment in gene-editing technologies and stem cell research for neurodegenerative diseases
    • 5.1.3.2. Potential utilization of nanomaterials for innovative drug formulation
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities of CNS disorders coupled with difficulty in crossing the blood-brain barrier
• 5.2. Market Segmentation Analysis
  • 5.2.1. Disorders: Increasing epileptic disorder prevalence and significant unmet medical needs
  • 5.2.2. Drug Type: Innovative biologics for particular and potent treatments
  • 5.2.3. Route of Administration: High preference for injectable routes owing to their long-acting formulations
  • 5.2.4. End-Users: Significant demand for CNS therapeutics in hospitals for immediate interventions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Central Nervous System Therapeutics Market, by Disorders

• 6.1. Introduction
• 6.2. Epileptic Disorders
  • 6.2.1. Epilepsy
  • 6.2.2. Seizure Disorders
• 6.3. Neurodegenerative Diseases
  • 6.3.1. Alzheimer's Disease
  • 6.3.2. Amyotrophic Lateral Sclerosis
  • 6.3.3. Multiple Sclerosis
  • 6.3.4. Parkinson's Disease
• 6.4. Pain Management
  • 6.4.1. Acute Pain
  • 6.4.2. Chronic Pain
  • 6.4.3. Neuropathic Pain
• 6.5. Psychiatric Disorders
  • 6.5.1. Anxiety Disorders
  • 6.5.2. Bipolar Disorder
  • 6.5.3. Depression
  • 6.5.4. Schizophrenia

7. Central Nervous System Therapeutics Market, by Drug Type

• 7.1. Introduction
• 7.2. Biologics
  • 7.2.1. Gene Therapies
  • 7.2.2. Monoclonal Antibodies
  • 7.2.3. Peptides
  • 7.2.4. Stem Cell Therapies
• 7.3. Small Molecules

8. Central Nervous System Therapeutics Market, by Route of Administration

• 8.1. Introduction
• 8.2. Injectable
  • 8.2.1. Intramuscular
  • 8.2.2. Intravenous
  • 8.2.3. Subcutaneous
• 8.3. Oral
• 8.4. Transdermal

9. Central Nervous System Therapeutics Market, by End-Users

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Research Institutes
• 9.4. Specialty Clinics

10. Americas Central Nervous System Therapeutics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Central Nervous System Therapeutics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Central Nervous System Therapeutics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Amneal Pharmaceuticals receives FDA approval for CREXONT to enhance Parkinson's therapy
  • 13.3.2. Asceneuron secures USD 100M to advance ASN51 for neurodegenerative diseases
  • 13.3.3. Eli Lilly's Kisunla receives FDA approval for early Alzheimer's treatment
  • 13.3.4. Roche and Ascidian Therapeutics join forces to develop innovative RNA therapies for neurological diseases
  • 13.3.5. Voyager Therapeutics initiates Phase 1a trial of VY-TAU01 for Alzheimer's
  • 13.3.6. Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830
  • 13.3.7. Sanofi India partners with Cipla to enhance distribution and promotion of CNS therapeutics to improve patient outcomes
  • 13.3.8. Engrail Therapeutics secures USD 157M Series B funding to advance non-addictive CNS therapies and expand strategic partnerships
  • 13.3.9. Myrobalan Therapeutics secures USD 24 million in Series A funding to advance CNS treatments
  • 13.3.10. AbbVie launches Produodopa, a groundbreaking 24-hour subcutaneous infusion therapy for advanced Parkinson's in the EU
  • 13.3.11. 4D Molecular Therapeutics and Arbor Biotechnologies partner to advance innovative genetic therapies for CNS disorders
  • 13.3.12. MapLight Therapeutics secures USD 225 million Series C funding to advance CNS therapies
  • 13.3.13. Pharmanovia expands neurology portfolio by acquiring 11 CNS brands from Sanofi
  • 13.3.14. Novartis strengthens neuroscience pipeline with USD 500M acquisition of siRNA-focused DTx Pharma
  • 13.3.15. Neurocrine Biosciences collaborates with Voyager Therapeutics on USD 175M gene therapy deal
• 13.4. Strategy Analysis & Recommendation
  • 13.4.1. F. Hoffmann-La Roche AG
  • 13.4.2. Bristol-Myers Squibb Company
  • 13.4.3. Lupin Limited
  • 13.4.4. AbbVie Inc.

Companies Mentioned

• 1. AbbVie Inc.
• 2. AC Immune SA
• 3. Acadia Pharmaceuticals Inc.
• 4. Acorda Therapeutics, Inc.
• 5. Alkermes PLC
• 6. Amgen Inc.
• 7. AstraZeneca PLC
• 8. Bayer AG
• 9. Biogen Inc.
• 10. Bristol-Myers Squibb Company
• 11. C.H. Boehringer Sohn AG & Co. KG
• 12. Cassava Sciences, Inc.
• 13. Cipla Limited
• 14. CNS Pharmaceuticals, Inc.
• 15. Denali Therapeutics Inc.
• 16. Eisai Co. Ltd.
• 17. Eli Lilly and Company
• 18. F. Hoffmann-La Roche AG
• 19. GlaxoSmithKline PLC
• 20. H. Lundbeck A/S
• 21. Intra-Cellular Therapies, Inc.
• 22. Ipsen S.A.
• 23. Johnson & Johnson Services, Inc.
• 24. Lupin Limited
• 25. MapLight Therapeutics, Inc.
• 26. Merck KGaA
• 27. Minerva Neurosciences, Inc.
• 28. Neuraxpharm
• 29. Novartis AG
• 30. Novo Nordisk A/S
• 31. Otsuka Holdings Co Ltd
• 32. Pfizer Inc.
• 33. Polpharma Biologics S.A.
• 34. Rapport Therapeutics, Inc.
• 35. Sage Therapeutics, Inc.
• 36. Sanofi S.A.
• 37. Sun Pharmaceutical Industries Limited
• 38. Supernus Pharmaceuticals, Inc.
• 39. Takeda Pharmaceutical Company Limited
• 40. TauRx Pharmaceuticals Ltd
• 41. Teva Pharmaceutical Industries Ltd.
• 42. UCB S.A.